Cell Therapeutics, Inc. (CTIC) announced that Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an overview of the company's pixantrone phase II and phase III clinical studies that demonstrated high rates of complete remission in relapsed/refractory aggressive and indolent non-Hodgkin's lymphoma, or NHL, patients.
The company revealed 70% CR/CRu rate in a phase II trial in patients treated with pixantrone plus FPD-R regimen in relapsed/refractory indolent NHL. The company also announced 47% CR/CRu rate in a phase II trial in patients treated with CPOP regimen for patients that failed CHOP regimen with relapsed/refractory aggressive NHL. Cell Therapeutics further disclosed 35% CR rate in a phase III trial in patients treated with pixantrone plus rituximab in relapsed/refractory indolent NHL.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.